A5014254979- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Pharmacology and Obesity Treatment
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Ovarian function and disorders
- Metabolism, Diabetes, and Cancer
- Autoimmune Bullous Skin Diseases
- Growth Hormone and Insulin-like Growth Factors
- Diabetes Treatment and Management
- Urticaria and Related Conditions
- Chronic Myeloid Leukemia Treatments
- Immune Response and Inflammation
- Diet, Metabolism, and Disease
- Dupuytren's Contracture and Treatments
- Vasculitis and related conditions
- Assisted Reproductive Technology and Twin Pregnancy
- Allergic Rhinitis and Sensitization
- Reproductive Biology and Fertility
- Psoriasis: Treatment and Pathogenesis
- Diet and metabolism studies
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Peripheral Artery Disease Management
Pfizer (United States)
2023-2024
Novartis (Switzerland)
2020-2022
Novartis Institutes for BioMedical Research
2021
Novartis (United States)
2019-2020
Immune-stimulator antibody conjugates (ISAC) combining tumor-targeting monoclonal antibodies with immunostimulatory agents allow targeted delivery of immune activators into tumors. NJH395 is a novel, first-in-class ISAC comprising Toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 via noncleavable linker payload. Preclinical characterization showed ISAC-mediated activation myeloid cells in the presence antigen-expressing cancer cells, antigen targeting and TLR7 agonism...
BACKGROUND There is an unmet need for a safer and more effective treatment obesity. This study assessed the effects of licogliflozin, dual inhibitor sodium‐glucose co‐transporter (SGLT) 1/2, on body weight, metabolic parameters incretin hormones in patients with type 2 diabetes mellitus (T2DM) and/or METHODS Patients obesity (BMI, 35‐50 kg/m ) were enrolled into 12‐week (N = 88; licogliflozin 150 mg q.d.). T2DM second, two‐part study, comprising single‐dose cross‐over 12; 2.5 − 300 mg)...
Extensive atherosclerotic plaque burden in the lower extremities often leads to symptomatic peripheral artery disease (PAD) including impaired walking performance and claudication. Interleukin-1β (IL-1β) may play an important pro-inflammatory role pathogenesis of this disease. Interruption IL-1β signaling was hypothesized decrease progression leg macrovasculature improve mobility patients with PAD intermittent Thirty-eight (mean age 65 years; 71% male) (confirmed by ankle–brachial index)...
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and insulin resistance. The dual sodium-glucose co-transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) ameliorates hyperinsulinism in patients with diabetes obesity. This study examines the effect of on androgens women PCOS. In a multicentre, randomized, placebo-controlled, double-blind, 2-week trial, PCOS received 50 mg or placebo three times day (TID). Changes free testosterone (FT), other variables resistance...
Importance Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments few application site reactions. Objective To assess the efficacy safety of phosphodiesterase 4 inhibitor PF-07038124 in patients AD psoriasis. Design, Setting, Participants This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across countries. Eligible (aged 18-70 years) had mild moderate...
<h3>Background</h3> NJH395 is a first-in-class immune stimulator antibody conjugate (ISAC) consisting of toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 antibody. Antibody-mediated delivery TLR7 may limit systemic toxicities previously seen with TLR agonists, while enhancing long-lasting antitumor response. In preclinical studies, showed promising activity in HER2 expressing xenograft mouse models, and demonstrated immunogenicity cytokine release mice nonhuman primates....
Treatment with licogliflozin, a dual sodium-glucose co-transporter (SGLT)1/2-inhibitor, is associated increased stool frequency and loose stools, attributed to SGLT1 inhibition. To investigate the effect of carbohydrate content supplements on licogliflozin-induced randomized, open-label, two-part (N = 24/part), three-period crossover study was carried out in overweight or obese adults. Significantly higher (P < 0.01) change from baseline 3-day total number bowel movements observed following...
Background: LIK066 is a potent dual inhibitor of SGLT1/2 (IC50: 20.6 and 0.58 nM for SGLT1 SGLT2). We studied mechanistic effects inhibition in the gut kidneys. Methods: Effects on weight, glucose variety incretin hormones (GLP-1, PYY, GIP, glucagon, insulin) were investigated in: 1) single dose cross-over study T2DM, 2) 14 day randomized, double-masked 3) 12-week double-masked, placebo-controlled obese subjects with normoglycemia (NG) or dysglycemia (DG; HbA1c: ≥5.7% &lt;10%). Results:...
Supplementary Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2<sup>+</sup> Malignancies
Licogliflozin versus placebo in women with polycystic ovary syndrome (PCOS): a randomised, double-blind, phase 2 trial.Background: PCOS is the most common endocrinopathy of childbearing age. Currently, there no approved therapy available. The dual sodium-glucose transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) ameliorates hyperinsulinism patients diabetes and obesity. Its effect on androgens unknown.Methods: In multi-center, placebo-controlled, double-blind trial, type A or B...
Supplementary Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2<sup>+</sup> Malignancies
Supplementary Figure from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2<sup>+</sup> Malignancies
Supplementary Figure from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2<sup>+</sup> Malignancies
<div>Abstract<p>Immune-stimulator antibody conjugates (ISAC) combining tumor-targeting monoclonal antibodies with immunostimulatory agents allow targeted delivery of immune activators into tumors. NJH395 is a novel, first-in-class ISAC comprising Toll‐like receptor 7 (TLR7) agonist conjugated to an anti-HER2 via noncleavable linker payload. Preclinical characterization showed ISAC-mediated activation myeloid cells in the presence antigen-expressing cancer cells, antigen targeting...
<div>Abstract<p>Immune-stimulator antibody conjugates (ISAC) combining tumor-targeting monoclonal antibodies with immunostimulatory agents allow targeted delivery of immune activators into tumors. NJH395 is a novel, first-in-class ISAC comprising Toll‐like receptor 7 (TLR7) agonist conjugated to an anti-HER2 via noncleavable linker payload. Preclinical characterization showed ISAC-mediated activation myeloid cells in the presence antigen-expressing cancer cells, antigen targeting...